LLY

725.55

+0.11%↑

JNJ

181.43

+1%↑

ABBV

221.67

+0.43%↑

UNH

343.11

-0.31%↓

NVO

55.42

-0.32%↓

LLY

725.55

+0.11%↑

JNJ

181.43

+1%↑

ABBV

221.67

+0.43%↑

UNH

343.11

-0.31%↓

NVO

55.42

-0.32%↓

LLY

725.55

+0.11%↑

JNJ

181.43

+1%↑

ABBV

221.67

+0.43%↑

UNH

343.11

-0.31%↓

NVO

55.42

-0.32%↓

LLY

725.55

+0.11%↑

JNJ

181.43

+1%↑

ABBV

221.67

+0.43%↑

UNH

343.11

-0.31%↓

NVO

55.42

-0.32%↓

LLY

725.55

+0.11%↑

JNJ

181.43

+1%↑

ABBV

221.67

+0.43%↑

UNH

343.11

-0.31%↓

NVO

55.42

-0.32%↓

Search

Biogen Inc

Aperta

SettoreSettore sanitario

138.59 0.85

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

135.28

Massimo

138.63

Metriche Chiave

By Trading Economics

Entrata

394M

635M

Vendite

215M

2.6B

P/E

Media del settore

13.46

35.69

EPS

3.02

Margine di Profitto

23.995

Dipendenti

7,605

EBITDA

457M

1B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+21.72% upside

Dividendi

By Dow Jones

Utili prossimi

29 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.9B

21B

Apertura precedente

137.74

Chiusura precedente

138.59

Notizie sul Sentiment di mercato

By Acuity

50%

50%

131 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Biogen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 set 2025, 18:25 UTC

I principali Market Mover

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28 set 2025, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28 set 2025, 23:48 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

28 set 2025, 23:45 UTC

Discorsi di Mercato

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28 set 2025, 23:34 UTC

Discorsi di Mercato

Oil Falls on Likely Technical Correction -- Market Talk

27 set 2025, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

26 set 2025, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 set 2025, 20:54 UTC

Utili

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 set 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

26 set 2025, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 set 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

26 set 2025, 19:54 UTC

Discorsi di Mercato

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 set 2025, 19:53 UTC

Acquisizioni, Fusioni, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 set 2025, 19:40 UTC

Utili

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 set 2025, 19:24 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 set 2025, 19:17 UTC

Discorsi di Mercato

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 set 2025, 19:15 UTC

Discorsi di Mercato

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 set 2025, 19:03 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

26 set 2025, 19:03 UTC

Discorsi di Mercato

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 set 2025, 18:50 UTC

Discorsi di Mercato
Utili

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 set 2025, 18:36 UTC

Discorsi di Mercato

Silver Closes Out Week With Strong Surge -- Market Talk

26 set 2025, 18:02 UTC

Acquisizioni, Fusioni, Takeovers

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 set 2025, 18:02 UTC

Acquisizioni, Fusioni, Takeovers

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 set 2025, 18:02 UTC

Acquisizioni, Fusioni, Takeovers

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 set 2025, 17:54 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 set 2025, 16:56 UTC

Discorsi di Mercato
Utili

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 set 2025, 16:41 UTC

Discorsi di Mercato
Utili

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 set 2025, 16:26 UTC

Utili

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 set 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Biogen Inc Previsione

Obiettivo di Prezzo

By TipRanks

21.72% in crescita

Previsioni per 12 mesi

Media 167.2 USD  21.72%

Alto 224 USD

Basso 118 USD

Basato su 26 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Biogen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

26 ratings

12

Acquista

14

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

118.15 / 121.17Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

131 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat